header logo image


Page 42«..1020..41424344..5060..»

Skye Bioscience to Announce Third Quarter 2024 Results

November 3rd, 2024 2:40 am

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET.

Link:
Skye Bioscience to Announce Third Quarter 2024 Results

Read More...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 3rd, 2024 2:40 am

CLEVELAND, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

See more here:
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More...

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

November 3rd, 2024 2:40 am

CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

More here:
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Read More...

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

November 3rd, 2024 2:40 am

BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024.

Originally posted here:
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

Read More...

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

November 3rd, 2024 2:40 am

Conference call to be held Monday, November 4, 2024, at 8:30 AM ET Conference call to be held Monday, November 4, 2024, at 8:30 AM ET

See the original post:
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Read More...

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

November 3rd, 2024 2:40 am

Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3)1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.

Continued here:
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

Read More...

Galecto Reports Third Quarter 2024 Financial Results

November 3rd, 2024 2:40 am

-  Completed strategic review to focus on oncology and severe liver diseases

Here is the original post:
Galecto Reports Third Quarter 2024 Financial Results

Read More...

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

November 3rd, 2024 2:40 am

CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "QLGN." The new CUSIP number for the common stock will be 74754R 301.

Here is the original post:
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Read More...

Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

November 3rd, 2024 2:40 am

Press Release – No. 10 / 2024

Read this article:
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results

Read More...

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

November 3rd, 2024 2:40 am

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.

See original here:
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Read More...

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and…

November 3rd, 2024 2:40 am

TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.1 In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.1 These studies, highlighting the patient focused outcomes, were presented at Psych Congress 2024 taking place from October 29 – November 2, 2024, in Boston, MA.

More here:
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and...

Read More...

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on…

November 3rd, 2024 2:40 am

TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO® XR® (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.

Here is the original post:
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on...

Read More...

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

November 3rd, 2024 2:40 am

Ji’an, Jiangxi, China, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on October 25, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.

See the original post:
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Read More...

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

November 3rd, 2024 2:39 am

WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST.

The rest is here:
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Read More...

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

November 3rd, 2024 2:39 am

PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of incorporation with the Secretary of State of the State of Delaware. The Company expects that its common stock will begin trading on a split-adjusted basis when the market opens on November 8, 2024, under its current trading symbol “LIPO.” Following the reverse stock split, the CUSIP number for the Company’s common stock will be updated to 53630L209.

Read the original here:
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Read More...

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

November 3rd, 2024 2:39 am

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties.

Continue reading here:
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Read More...

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

November 3rd, 2024 2:39 am

TORONTO and HAIFA, Israel, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce, further to its press release dated September 26, 2024 (the “September 26 Release”), the closing of the final tranche of its previously announced non-brokered private placement (the “Offering”) for gross proceeds of $127,499.90 (“Tranche 2”). In the Offering, the Company raised aggregate gross proceeds of $1,737,647.45 through the issuance of 3,159,359 Units. Capitalized terms not otherwise defined herein have the meanings attributed to them in the September 26 Release.

Read the rest here:
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

Read More...

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer…

November 3rd, 2024 2:39 am

Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers

See original here:
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer...

Read More...

WHO launches first World report on vision

October 22nd, 2024 2:40 am

rnrnrn

Main causes of rising cases of vision impairment

Eye conditions that can cause vision impairment and blindness such as cataract, trachoma and refractive error are the main focus of national prevention and other eye care strategies. But eye conditions that do not typically impair vision, including dry eye and conjunctivitis, must not be overlooked as they are among the main reasons for people to seek eye health care services in all countries, the report states.

The combination of a growing and ageing population will significantly increase the total number of people with eye conditions and vision impairment, since prevalence increases with age.

Other main drivers of the most common eye conditions include:

Access to services

Stronger integration of eye care is needed within national health services, including at primary health care level, to ensure that the eye care needs of more people are addressed, including through prevention, early detection, treatment and rehabilitation, the report found.

Dr Alarcos Cieza, who heads WHOs work to address blindness and vision impairment, says: Millions of people have severe vision impairment and are not able to participate in society to their fullest because they cant access rehabilitation services. In a world built on the ability to see, l eye care services, including rehabilitation, must be provided closer to communities for people to achieve their maximum potential.

The report states that all people living with blindness and severe vision impairment who cannot be treated are still able to lead independent lives if they access rehabilitation services. Options include optical magnifiers and reading use Braille, to smartphone wayfinders and orientation and mobility training with white canes.

Read the WHO World report on vision summaryor the full report.

Read the original here:
WHO launches first World report on vision

Read More...

Eye health, vision impairment and blindness – World Health Organization …

October 22nd, 2024 2:40 am

Although effective interventions and coverage exist to the Region to address two the leading causes of vision impairment - refractive errors and cataracts countries are working to increase eye care. By 2030, all countries in the Region are working to increase effective coverage of refractive errors by 40% and an increase effective coverage of cataract surgery by 30%. Highly cost-effective interventions for these conditions, including spectacles and cataract surgery can substantially improve a persons quality of life.

Vision impairment that cannot be corrected or reversed requires rehabilitation measures, including low vision aids and assistive technologies. For those living with blindness, braille reading, counselling, home skills training, mobility training with white canes, and digital assistive technologies can ensure free, independent, and safe mobility.

To achieve better visual health in the Region, WHO is working closely with Member States and stakeholders, such as the International Agency for the Prevention of Blindness, The Fred Hollows Foundation, and the Singapore National Eye Care, to plan and deliver Integrated people-centered eye care (IPEC).

Treatment and care for many eye conditions can be improved by implementing IPEC, and promoting comprehensive treatment and intervention across the life course. Additionally, countries are also working to improve data on better treatment processes in order to improve overall care.

Go here to read the rest:
Eye health, vision impairment and blindness - World Health Organization ...

Read More...

Page 42«..1020..41424344..5060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick